Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.
about
Focus on cannabinoids and synthetic cannabinoids.Comparison of outcome expectancies for synthetic cannabinoids and botanical marijuana.Emerging and Underrecognized Complications of Illicit Drug Use.Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.Examination of Synthetic Cannabinoid and Cathinone Use among a Drug-Using Offender Sample, 2013-2015.Identification and analytical characterization of six synthetic cannabinoids NNL-3, 5F-NPB-22-7N, 5F-AKB-48-7N, 5F-EDMB-PINACA, EMB-FUBINACA, and EG-018.Toxicology in clinical laboratories: challenging times.Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence.Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health.The Growing Problem of New Psychoactive Substances (NPS).Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.Short and Divergent Total Synthesis of (+)-Machaeriol B, (+)-Machaeriol D, (+)-Δ(8)-THC, and Analogues.
P2860
Q30241053-A5B753BD-C6ED-4B53-8FC4-271D78BC2F27Q34515407-2C3383C0-9F25-4653-98C2-388477AED5F4Q34672276-66066C17-A1A7-4A2A-B667-AD74A75F7E48Q37637031-B7763968-FB60-44E4-952E-E3F750236ACAQ38376082-DFFD8B24-4943-4B14-9D42-4FE7F1217D82Q38622274-15CCF084-C64B-4667-B65C-8E85F3657D17Q39034523-321A4D21-2623-428C-AB0F-24C84DE27BD7Q39380629-C0D443AE-0F5C-4EE3-B484-A7D63D2A73C9Q39594599-64A567A4-AE55-4808-BBF8-126C8F9FCDFAQ40054798-A6772475-FA08-40C9-A1F6-B9D52124F6FAQ40603293-0C7EB5A4-714F-4AA4-AFB2-8D0BD18B5A80Q44346648-E481FAAD-1D35-404A-A66D-0DBE69C6C569Q50962895-30561B26-E932-4DAE-9249-05069E596987
P2860
Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@ast
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@en
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@nl
type
label
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@ast
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@en
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@nl
prefLabel
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@ast
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@en
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@nl
P2860
P1476
Synthetic cannabinoid use amon ...... ence, motives, and correlates.
@en
P2093
Erin E Bonar
Lisham Ashrafioun
P2860
P304
P356
10.1016/J.DRUGALCDEP.2014.07.009
P577
2014-07-17T00:00:00Z